DiagnosticLaunch & access18 Sept 2026Part one of two

The wrong clock

The Saudi FDA targets thirty working days on its fastest route. In oncology, the median wait from registration to public reimbursement has been twenty three months. Almost every Gulf launch plan is built around the first number.

Who this is for

Country and regional managers, market access and launch teams working in Saudi Arabia and the UAE. Most useful if you are setting a launch date, building a year one forecast, or being asked why revenue has not started.

Anita Menon

Commercial leadership across the GCC, India and APAC

The regulatory story in the Gulf is real and it is impressive. The Saudi FDA has held WHO Maturity Level 4 since October 2023. Three regulators in the world are at that level. Its published target is thirty working days on the verification route, sixty on the abridged one. No European regulator publishes anything like it. Worth saying plainly: these are targets. SFDA does not publish what it actually achieves, so nobody outside it can tell you how often they are hit.

Two things about that. Both fast routes only work if the FDA or the EMA has already approved the product, and only if you file within two years of that. A genuinely first-in-world Saudi filing qualifies for neither and drops to the full route, four hundred and five working days. So the speed is real, and it is built to follow the US and Europe rather than to lead them.

The second point matters more. Registration was never what held anyone up.

Where the time goesMedian months from first global launch, across 183 oncology new active substances launched between 2014 and 2023. Source: IQVIA Institute, August 2025. Two caveats that matter: this is oncology, not launches in general, and these launches predate the 2023 maturity upgrade. No comparable dataset yet measures what has happened since.

Registration is the cheap gate. Everything expensive happens after it.

This is the gap launch plans miss. The part of the system that got faster is the part companies are already good at managing. The part that did not is the part they are not. Five questions follow. They are all about the second half, and each wrong answer costs you something different.

The diagnostic

Five questions, in this order

Which NUPCO tender window are you launching into, and what is its date?

Not a quarter. A named tender with an opening date.

If nobody can name it NUPCO's published plan for 2026 contains four pharmaceutical tenders for the entire year, and roughly four months run from opening to final award. The date in your launch plan is a registration date, not a revenue date. If your category was tendered recently on a multi-year framework, the honest answer may be next year.

Who is your first customer: NUPCO, a cluster, or an insurer?

Name the entity that signs.

If the plan says the Ministry of Health It describes the system as it was. NUPCO holds the framework price, the twenty regional clusters increasingly decide volume, and the transfer of those clusters to the Health Holding Company was still running through 2026. The Council of Health Insurance is being positioned as the strategic purchaser. Three buyers, mid-transition, and no single door to knock on.

Where does your Gulf price land, and which markets inherit it?

List the downstream markets by name.

If the list is empty Saudi Arabia references a basket of sixteen countries, and the Gulf Committee for Pharmaceutical Pricing works to harmonise prices across the member states, so a Saudi price does not stay in Saudi Arabia. Morocco's pricing decree references Saudi Arabia as one of only six countries and takes the lowest. Egypt was reported in September 2026 to have cut its own basket to fifteen, added the UAE, and to take the lowest minus a further ten per cent. You are pricing one market and setting price across several.

Is your economic evaluation built on Saudi data?

Open it and look for local epidemiology.

If it is a European dossier with the currency changed SFDA made economic evaluation mandatory from 1 July 2025 for new registrations, price re-evaluations and renewals. This gate arrived at the exact moment regulatory review got faster, which is why the front and the back of the Saudi system are now moving in opposite directions.

What is your localisation answer, and who signed it?

Ask to see the document.

If the answer is that you are exploring options Since February 2025 the local content authority stacks an additional pharmaceutical price preference of up to twenty per cent on the standard ten. You can be evaluated at a thirty per cent disadvantage to a local alternative. Secondary packaging alone does not count. The template is the Sanofi, NUPCO and Sudair insulin agreement of October 2024: guaranteed volume in exchange for technology transfer.

Reading the pattern

Fail on one and two and you have a calendar problem. The plan may be sound and the date wrong by a year. This is the cheapest failure to fix and the only one you can fix after the launch date is announced, which is to say you cannot.

Fail on three and a pricing decision is being made by people who believe they are making a timing decision. It costs the most, it surfaces last, and it surfaces in markets nobody on the launch team is accountable for.

Fail on four or five and you are competing on the terms of the old system. Both gates are new, both are getting heavier, and neither is solved by a better dossier.

One correction worth making inside your own organisation, stated at the strength the evidence allows. No European or United States reference basket appears to include Saudi Arabia or the UAE anywhere in the published pricing literature. That is a negative finding rather than proof of absence, but it points firmly one way: the price spillover from the Gulf runs into North Africa and the Levant, not into your American or European price. Fear of global spillover is often the stated reason for delaying a Gulf launch that would otherwise pay.

These are the rules as published in September 2026, in a system that is moving quickly. SFDA has posted a consultation on updated pricing rules. The cluster transition is incomplete. Check the primary sources before you plan a 2027 launch on any of it.

On sources

Every figure here comes from a named, dated source: the Saudi FDA's own regulatory framework and pricing rules, NUPCO's published tender plan, the Local Content and Government Procurement Authority, the World Health Organization, the IQVIA Institute and Vision 2030 programme reporting.

Three things are worth stating rather than burying. Published review timelines are targets, because SFDA does not publish achieved times. The access figures are oncology and predate the 2023 maturity upgrade. And two claims here rest on credible secondary reporting of Saudi government documents rather than on the documents themselves, because those sites are not publicly retrievable: the July 2025 economic evaluation mandate and the February 2025 change to the local content preference. Both are consistent across independent reports. Neither has been verified against the primary document.

One page

Take it into the room

The same five questions on a single A4 sheet, sized to print and hand across a table.

Download the PDF →

Part two: Southeast Asia

The same question asked of Indonesia, Vietnam, Thailand, Malaysia, the Philippines and Singapore, where registration also got faster and the formulary calendar did not. Coming shortly.

Tell me what needs to change →